HIV-infecteda | HIV-uninfected | |||||
---|---|---|---|---|---|---|
Total (N = 284) | TBb (N = 66) | Unlikely TBc (N = 218) | Total (N = 235) | TBb (N = 51) | Unlikely TBc (N = 184) | |
Age—days | ||||||
Median | 95 | 96 | 95 | 93# | 93 | 93# |
Range | 91 to 120 | 91 to 120 | 91 to 120 | 91 to 120 | 91 to 119 | 91 to 120 |
WHO weight-for-age z score | ||||||
Median | − 1.35 | − 1.39 | − 1.10 | − 0.33# | − 0.46# | − 0.30# |
Range | − 5.84 to 3.48 | − 5.84 to 2.17 | − 5.84 to 3.48 | − 4.96 to 1.98 | − 4.96 to 1.87 | − 3.34 to 1.98 |
Male sex—no. (%) | 116 (40.8) | 29 (42.4) | 87 (39.9) | 126 (53.6)# | 27 (52.9)# | 99 (53.8)# |
Race or ethnic group—no. (%) | ||||||
Indigenous African | 283 (99.6) | 66 (100.0) | 217 (99.5) | 234 (99.6) | 51 (100.0) | 183 (99.5) |
Mixed ancestry or other | 1 (0.4) | 0 (0.0) | 1 (0.5) | 1 (0.4) | 0 (0.0) | 1 (0.5) |
Breast-feeding—no. (%) | ||||||
Ever breast-fed | 42 (14.8) | 6 (9.1) | 36 (16.5) | 19 (8.1)# | 2 (4.0) | 17 (9.2)# |
Breast-fed at baseline | 22 (7.7) | 4 (6.1) | 18 (8.3) | 3 (1.3)# | 0 (0.0) | 3 (1.6)# |
Parent study arm—no. (%)d | ||||||
Isoniazid | 150 (52.8) | 33 (50.0) | 117 (53.7) | 113 (48.1) | 23 (45.1) | 90 (48.9) |
Placebo | 134 (47.2) | 33 (50.0) | 101 (46.3) | 122 (51.9) | 28 (54.9) | 94 (51.1) |
Maternal history of tuberculosis—no. (%) | 13 (4.6) | 5 (7.6) | 8 (3.7) | 15 (6.8) | 3 (5.9) | 12 (6.5) |
During index pregnancy | 1 (0.4) | 1 (1.5) | 0 | 1(0.4) | 0 | 1 (0.5) |
Before index pregnancy | 12 (4.2) | 4 (6.1) | 8 (3.7) | 14 (6.4) | 3 (5.9) | 11 (6.0) |
CDC clinical HIV category—no. (%)e | ||||||
N (asymptomatic) | 223 (79.6) | 53 (81.5) | 170 (79.1) | – | – | – |
A (mildly symptomatic) | 43 (15.4) | 9 (13.9) | 34 (15.8) | – | – | – |
B (B moderately symptomatic) | 14 (5.0) | 3 (4.6) | 11 (5.1) | – | – | – |
CD4+ percentage—% | ||||||
Median | 30 | 25 | 30ǂ | – | – | – |
Range | 6 to 58 | 9 to 48 | 6 to 58 | – | – | – |
CD4+ percentage category—no. (%)f | ||||||
< 20% | 52 (19.7) | 14 (23.7) | 38 (17.7) | – | – | – |
20–24% | 33 (12.5) | 14 (23.7) | 29 (13.5) | – | – | – |
25–34% | 104 (39.4) | 21 (35.6) | 83 (38.6) | – | – | – |
≥ 35% | 75 (28.4) | 10 (16.9) | 65 (30.2) | – | – | – |
Plasma HIV-1 RNA at entry—copies/ml | ||||||
Median | 527,000 | 750,000 | 386,000ǂ | – | – | – |
Range | ≤ 400 to > 750,000 | ≤ 400 to > 750,000 | ≤ 400 to > 750,000 | – | – | – |
TB related parameters—n/N (%)g | ||||||
MTB culture | 5/111 (4.5) | 5/61 (8.2) | 0/50 (0.0) | 5/68 (7.4) i | 5/42 (11.9) | 0/26 (0.0) |
AFB smear | 14/114 (12.3) | 9/64 (14.1) | 5/50 (10.0) | 9/70 (12.9) | 6/44 (13.6) | 3/26 (11.5) |
TST | 78/202 (38.6) | 46/66 (69.7) | 32/136 (23.5)ǂ | 51/226 (22.6)# | 30/51 (58.8) | 21/175 (12.0)#ǂ |
TB contact exposure | 39/41 (95.1) | 27/28 (96.4) | 12/13 (92.3) | 34/38 (89.5) | 21/24 (87.5) | 13/14 (92.9) |
Chest X-ray | 75/134 (56.0) | 58/66 (87.9) | 17/68 (25.0)ǂ | 61/98 (62.2) | 49/51 (96.1) | 12/47 (25.5)ǂ |
Signs/symptoms consistent with TB | 13/284 (4.6) | 10/66 (15.2) | 3/218 (1.4)ǂ | 11/235 (4.7) | 6/51 (11.8) | 5/184 (2.7)ǂ |
Positive response to anti-TB therapyh | 38/77 (49.4) | 37/60 (61.7) | 1/17 (5.9)ǂ | 33/61 (54.1) | 32/46 (69.6) | 1/15 (6.7)ǂ |